Athena Heart 310 Official

The treatment has been generally well-tolerated, with minor side effects like back pain or nausea reported during infusion. 🧬 Mechanism and Targets

Mean reductions of ~49%, with peak effects reaching 87% . ATHENA HEART 310

Targeted protein levels decreased by an average of 73%. The treatment has been generally well-tolerated, with minor

(often associated with ATHENA trial contexts in heart disease research) is an experimental in vivo CRISPR gene-editing therapy designed to provide a one-time treatment for cardiovascular disease risk factors. It specifically targets the ANGPTL3 gene in the liver to permanently lower high levels of triglycerides (TG) and "bad" LDL cholesterol. 💡 Key Trial Results (Phase 1) (often associated with ATHENA trial contexts in heart

As of early 2026, the program is advancing toward to further evaluate long-term outcomes and safety in larger patient populations. This technology represents a potential shift from chronic disease management to a "one-and-done" therapeutic model for heart health.

ANGPTL3 is a protein that normally inhibits enzymes that clear lipids from the blood. By "turning off" this gene, the body can more effectively remove fats.

Unlike daily pills or bi-monthly injections, CTX310 aims for a durable, permanent solution by editing DNA directly: